A Phase 2 interventional study of Lofexidine and Placebo in Opioid Withdrawal (Disorder), sponsored by USWM, LLC (dba US WorldMeds). Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by USWM, LLC (dba US WorldMeds) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Stopping prescription opioid pain medications can be difficult due to withdrawal symptoms. This study will test if LUCEMYRA helps reduce withdrawal symptoms and helps more people reduce their opioid dose compared to placebo.
This randomized, double-blind, placebo-controlled pilot study will evaluate the safety and effectiveness of LUCEMYRA in the treatment of opioid withdrawal during an opioid taper in subjects with chronic non-cancer pain.
Subjects will begin a planned 14-day complete taper of their pre-study opioid medications and will be randomly assigned (1:1) to either LUCEMYRA or matching placebo. Study drug will be administered through the opioid taper and for 5 days after the opioid taper is completed. Study drug will then be tapered over a 4-day period for a total of approximately 21 days exposure to study drug.
USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lofexidine
Drug: Placebo
Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
Also known as: lofexidine hydrochloride, LUCEMYRA
Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
Number of Treatment Emergent AEs and SAEs
Time frame: Day 1 through Day 28
Number and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation
Time frame: Day 1 through Day 28
Percentage of Subjects With Treatment-emergent Elevated Liver Function Tests
Time frame: Day 1 through Day 28
Percentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale
The C-SSRS measures both suicidal ideation and suicidal behavior. The Screener contains "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide. A significant risk of suicide is defined as a "yes" in answer to: a) questions 4 or 5 on the suicidal ideation section, or b) any questions on any item in the suicidal behavior section. This must be reported as an SAE and followed up accordingly. Additionally, if a subject responds "yes" to any of the suicidal ideation questions 1 to 3, the Investigator should apply clinical judgment to determine the need for reporting as an AE or SAE and the need for any referral.
Time frame: Day 1 through Day 28
Change in Blood Pressure
Orthostatic vital signs were measured in-clinic only. When the subject is at home, only resting vital signs will be collected. Orthostatic vital signs will be measured first after the subject has been sitting for at least 5 minutes and then after the subject has been standing for at least 3 minutes. Resting vital signs only will be measured at home and will be measured after the subject has been sitting quietly for at least 5 minutes.
Time frame: Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Change in Pulse
Time frame: Baseline to Days 1, 2, 3, 7, 8, 14, 15, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Percentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation
Time frame: Day 1 through Day 28
Change in Clinical Opiate Withdrawal Scale (COWS)
The COWS is a clinician-administered instrument that rates 11 common opioid withdrawal signs and symptoms. These include: resting pulse rate; sweating; restlessness; pupil size; bone or joint aches; runny nose or tearing; gastrointestinal upset; tremor; yawning; anxiety or irritability; and gooseflesh skin. Lower total scores indicate a more positive clinical outcome. Score: 5-12 = mild; 13-24 = moderately severe; more than 36 = severe withdrawal. Scores range from a minimum of 0 to a maximum of 48.
Time frame: Day 1 (pre-1st dose) to Days 3, 8, 15, 22 and 28
Change in the Short Opiate Withdrawal Scale of Gossop (SOWS-G)
The SOWS-Gossop scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 10 items that are scored on a 4-point scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe (minimum score of 0, maximum score of 30). The overall score is the simple sum of the 10 item scores. Lower observed values in SOWS-Gossop scores indicate a more positive clinical outcome.
Time frame: Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Change in Subjective Opiate WIthdrawal Scale of Handelsman (SOWS-H)
The SOWS-H scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 19 items that are scored on a 5-point scale of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. The overall score is the simple sum of the 19 item scores. Lower observed values in SOWS-H scores indicate a more positive clinical outcome.
Time frame: Day 1 (pre-1st dose) to Days 1 (at bedtime), 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28
Modified Clinical Global Impression - Rater Version (MCGI-R) Average Score
MCGI-R includes 2 items: A 7-point scale that allows clinicians to rate the severity of a subject's opiate withdrawal symptoms. A 4-point scale that allows clinicians to rate the degree of a subject's side effects from study drug. SEVERITY OF ILLNESS: 1. = No at all ill 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Among the most extremely ill subjects SIDE EFFECTS INDEX: 1. = None, study drug is producing no side effects 2. = Do not significantly interfere with subject's functioning 3. = Significantly interferes with subject's functioning 4. = Outweighs therapeutic effect
Time frame: Each scheduled evaluation (Study Visits 2, 3, 4, 5, EOS)
Modified Clinical Global Impression - Subject Version (MCGI-S)
Includes: A 7-point scale for subjects to rate the severity of opiate withdrawal symptoms. A 4-point scale for subjects to rate the degree of side effects from their study drug. SEVERITY OF OPIATE WITHDRAWAL: 1. = No opiate withdrawal symptoms 2. = On the border between no to mild opiate withdrawal symptoms 3. = Mild opiate withdrawal symptoms 4. = Moderate opiate withdrawal symptoms 5. = Marked opiate withdrawal symptoms 6. = Severe opiate withdrawal symptoms 7. = The most severe opiate withdrawal symptoms that I have ever had SIDE EFFECTS INDEX (Scale B): 1. = None. The study drug has no side effects 2. = The study drug has slight side effects, but it does NOT significantly interfere with my day to day activities 3. = The study drug has moderate side effects, and it DOES significantly interfere with my day to day activities 4. = The study drug has severe side effects, and these side effects are greater than the relief from opiate withdrawal symptoms that it provides
Time frame: Each scheduled evaluation (Day 1 through Day 28)
Time to Study Drug Discontinuation
Study day of participant discontinuation.
Time frame: Day 1 through Day 28
Number of Non-opioid Concomitant Medications for Withdrawal Symptoms Used by Study Day
Time frame: Day 1 through Day 28
Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale
The EQ-5D-5L is an instrument that evaluates preference for health status through 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of which are rated on 5 levels of severity. Each dimension ranges from a minimum of "0 - I have no problems or I am not" to a maximum of "5 - I am unable to or I am extremely". The dimensions are averaged together for a single score and the change in average score from baseline is recorded.
Time frame: Change from Baseline to EOS
Change in Short Form Health Survey (SF-36) Scale
The SF-36 consists of 36 questions that measure various aspects of physical and mental well-being. Precoded values are recorded for each question ranging from 0-100, with a high score defined as a more favorable health status. The items are then averaged together to create the 8 scale scores which are averaged together to create a scale. The final value reported is the average change in the averaged scale scores from baseline to end of study.
Time frame: Change from baseline to End of Study, up to 55 days
Change in Insomnia Severity Index (ISI)
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. The dimensions evaluated are: severity of sleep onset, sleep maintenance and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item on a scale 0 to 4 for each of the 7 items, yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
Time frame: Change from baseline to Days 15 and End of Study, up to 55 days
Change in Hospital Anxiety and Depression Scale (HADS)
The HADS is a self-reported screening tool for anxiety and depression in nonpsychiatric clinical populations. Responses are based on the relative frequency of symptoms over the preceding week. The scale consists of 14 items, with a subscale of 7 questions for anxiety and 7 questions for depression. Patients rate each item in the subscales on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). Possible scores range from 0 to 21 for each subscale. An analysis of scores on the 2 subscales supported the differentiation of each mood state into 4 ranges: non-cases (scores 0 to 7), mild cases (scores 8 to 10), moderate cases (scores 11 to 15), and severe cases (scores 16 or higher), with lower values being favorable. The subscales are then combined for a total score ranging from 0 to 42. Higher scores indicate greater levels of anxiety or depression. The value reported is the average change from baseline to End of Study.
Time frame: Change from End of Study to Baseline, up to 55 days
Change in Average Chronic Pain as Measured by the Numeric Rating Scale (NRS)
A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: Baseline through Follow-up (assessed daily)
Change in Average Overall Pain as Measured by the Numeric Rating Scale (NRS)
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: Day 1 through Day 28 (assessed daily)
Change in Worst Chronic Pain as Measured by the Numeric Rating Scale (NRS)
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: Baseline through Day 51 (assessed daily)
Change in Worst Overall Pain as Measured by the Numeric Rating Scale (NRS)
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
Time frame: Day 1 through Day 28 (assessed daily)
Change in Daily Opioid Dose Expressed as Morphine Equivalent Dose (MED)
Time frame: Baseline through Day 28
Change in Daily Opioid Dose as a Percentage of the Baseline MED
Time frame: Baseline through Day 28
| Milestone | Lofexidine | Placebo |
|---|---|---|
| Started | 1 | 3 |
| Completed | 0 | 2 |
| Not completed | 1 | 1 |
| participants | Lofexidine | Placebo |
|---|---|---|
| Adverse Events | 0 | 5 |
| Serious Adverse Events | 0 | 0 |
| Participants | Lofexidine | Placebo |
|---|---|---|
| Number and Percent of Subjects Reporting TEAEs Resulting in Study Drug Discontinuation | 0 | 1 |
| Participants | Lofexidine | Placebo |
|---|---|---|
| Percentage of Subjects With Treatment-emergent Elevated Liver Function Tests | 0 | 0 |
The C-SSRS measures both suicidal ideation and suicidal behavior. The Screener contains "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide. A significant risk of suicide is defined as a "yes" in answer to: a) questions 4 or 5 on the suicidal ideation section, or b) any questions on any item in the suicidal behavior section. This must be reported as an SAE and followed up accordingly. Additionally, if a subject responds "yes" to any of the suicidal ideation questions 1 to 3, the Investigator should apply clinical judgment to determine the need for reporting as an AE or SAE and the need for any referral.
| % of subjects with suicide risk | Lofexidine | Placebo |
|---|---|---|
| Percentage of Subjects Identified as Suicide Risk With Columbia Suicide Severity Rating Scale | 0 | 0 |
Orthostatic vital signs were measured in-clinic only. When the subject is at home, only resting vital signs will be collected. Orthostatic vital signs will be measured first after the subject has been sitting for at least 5 minutes and then after the subject has been standing for at least 3 minutes. Resting vital signs only will be measured at home and will be measured after the subject has been sitting quietly for at least 5 minutes.
| mmHg | Lofexidine: Sitting | Lofexidine: Standing | Placebo: Sitting | Placebo: Standing |
|---|---|---|---|---|
| Day 1: Diastolic BP | -2 ± NA | 0 ± NA | -0.3 ± 3.06 | -0.7 ± 3.21 |
| Day 1: Systolic BP | -6 ± NA | 0 ± NA | 1.7 ± 2.31 | -0.3 ± 1.53 |
| Day 2: Diastolic BP | -7 ± NA | — | 3 ± 5.66 | — |
| Day 2: Systolic BP | -25 ± NA | — | 7 ± 9.9 | — |
| Day 3: Diastolic BP | -16 ± NA | -9 ± NA | 1.5 ± 3.87 | 5 ± 6 |
| Day 3: Systolic BP | -52 ± NA | -44 ± NA | 6.5 ± 7.72 | 6 ± 7.94 |
| Day 7: Diastolic BP | -16 ± NA | — | 7 ± 8.72 | — |
| Day 7: Systolic BP | -50 ± NA | — | 6 ± 7 | — |
| Day 8: Diastolic BP | -10 ± NA | -8 ± NA | 3.3 ± 9.45 | 5.3 ± 5.86 |
| Day 8: Systolic BP | -44 ± NA | -36 ± NA | 4 ± 11 | 3 ± 11 |
| Day 14: Diastolic BP | -8 ± NA | — | 1.7 ± 10.5 | — |
| Day 14: Systolic BP | -42 ± NA | — | 4.7 ± 10.02 | — |
| Day 15: Diastolic BP | -10 ± NA | -4 ± NA | 1 ± 7.81 | 3.3 ± 7.77 |
| Day 15: Systolic BP | -32 ± NA | -40 ± NA | 10.7 ± 16.07 | 4.3 ± 13.01 |
| Day 18: Diastolic BP | — | — | 10.7 ± 6.35 | — |
| Day 18: Systolic BP | — | — | 14.3 ± 0.58 | — |
| Day 19: Diastolic BP | — | — | 6.3 ± 4.5 | — |
| Day 19: Systolic BP | — | — | 11 ± 6.22 | — |
| Day 20: Diastolic BP | — | — | 1.8 ± 5.91 | — |
| Day 20: Systolic BP | — | — | 4.3 ± 7.68 | — |
| Day 21: Diastolic BP | — | — | 8.5 ± 3.42 | — |
| Day 21: Systolic BP | — | — | 11.8 ± 11.12 | — |
| Day 22: Diastolic BP | -16 ± NA | -8 ± NA | 4.3 ± 3.72 | 10 ± 1.41 |
| Day 22: Systolic BP | -25 ± NA | -34 ± NA | 9.7 ± 16.02 | 16 ± 1.41 |
| Day 23: Diastolic BP | -3.5 ± NA | — | 3.5 ± 5.45 | — |
| Day 23: Systolic BP | -19 ± NA | — | 11.5 ± 12.23 | — |
| Day 24: Diastolic BP | -1.5 ± NA | — | 6.3 ± 4.5 | — |
| Day 24: Systolic BP | -23.5 ± NA | — | 9.5 ± 6.61 | — |
| Day 25: Diastolic BP | — | — | 4.7 ± 3.56 | — |
| Day 25: Systolic BP | — | — | 8.5 ± 9.57 | — |
| Day 26: Diastolic BP | 1.5 ± NA | — | 9.3 ± 7.46 | — |
| Day 26: Systolic BP | -14 ± NA | — | 8.5 ± 19.28 | — |
| Day 27: Diastolic BP | — | — | 4.8 ± 4.67 | — |
| Day 27: Systolic BP | — | — | 7.7 ± 8.16 | — |
| Day 28: Diastolic BP | — | — | 11 ± 7.07 | 7.5 ± 4.95 |
| Day 28: Systolic BP | — | — | 22 ± 7.07 | 15.5 ± 14.85 |
| Day 29: Diastolic BP | — | — | -0.5 ± NA | — |
| Day 29: Systolic BP | — | — | 18 ± NA | — |
| Day 30: Diastolic BP | — | — | -1.5 ± NA | — |
| Day 30: Systolic BP | — | — | 8 ± NA | — |
| Day 34: Diastolic BP | — | — | 0.5 ± NA | — |
| Day 34: Systolic BP | — | — | 12.5 ± NA | — |
| Day 37: Diastolic BP | — | — | 0 ± NA | 3 ± NA |
| Day 37: Systolic BP | — | — | -5 ± NA | -5 ± NA |
| bpm | Lofexidine: Sitting | Lofexidine: Standing | Placebo: Sitting | Placebo: Standing |
|---|---|---|---|---|
| Day 1 | 1 ± NA | 0 ± NA | -5 ± 2.65 | -0.3 ± 3.21 |
| Day 2 | -2 ± NA | — | -9 ± 4.24 | — |
| Day 3 | -4 ± NA | -5 ± NA | -7.3 ± 2.63 | -5.3 ± 0.58 |
| Day 7 | 0 ± NA | — | -2 ± 9.54 | — |
| Day 8 | -2 ± NA | -4 ± NA | -1 ± 3.46 | -0.7 ± 0.58 |
| Day 14 | -1 ± NA | — | -1.7 ± 7.09 | — |
| Day 15 | -2 ± NA | 0 ± NA | -11 ± 8.19 | -3 ± 3.46 |
| Day 18 | — | — | 1.7 ± 2.89 | — |
| Day 19 | — | — | -2.8 ± 4.03 | — |
| Day 20 | — | — | -8.8 ± 5.12 | — |
| Day 21 | — | — | -1.8 ± 8.54 | — |
| Day 22 | -4 ± NA | -5 ± NA | -6 ± 4.1 | -7 ± 2.83 |
| Day 23 | 0.5 ± NA | — | -4 ± 11.8 | — |
| Day 24 | -1 ± NA | — | -6.5 ± 4.2 | — |
| Day 25 | — | — | -0.8 ± 7.78 | — |
| Day 26 | 0.5 ± NA | — | -9 ± 4.97 | — |
| Day 27 | — | — | -5.5 ± 7.31 | — |
| Day 28 | — | — | -7.5 ± 3.54 | -7 ± 11.31 |
| Day 29 | — | — | 3.5 ± NA | — |
| Day 30 | — | — | 1.5 ± NA | — |
| Day 34 | — | — | 2.5 ± NA | — |
| Day 37 | — | — | -13 ± NA | -8 ± NA |
| Participants | Lofexidine | Placebo |
|---|---|---|
| Percentage of Subjects Who Successfully Complete Each Scheduled Dose Reduction and the Opioid Taper to Complete Opioid Discontinuation | 0 | 2 |
The COWS is a clinician-administered instrument that rates 11 common opioid withdrawal signs and symptoms. These include: resting pulse rate; sweating; restlessness; pupil size; bone or joint aches; runny nose or tearing; gastrointestinal upset; tremor; yawning; anxiety or irritability; and gooseflesh skin. Lower total scores indicate a more positive clinical outcome. Score: 5-12 = mild; 13-24 = moderately severe; more than 36 = severe withdrawal. Scores range from a minimum of 0 to a maximum of 48.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 3 | 2 | -0.7 ± 0.58 |
| Day 8 | 3 | -1 ± 2 |
| Day 15 | 4 | -1.3 ± 0.58 |
| Day 22 | -1 | -2.5 ± 0.71 |
| End of Study | -1 | -2.3 ± 0.58 |
The SOWS-Gossop scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 10 items that are scored on a 4-point scale of 0 = none, 1 = mild, 2 = moderate, and 3 = severe (minimum score of 0, maximum score of 30). The overall score is the simple sum of the 10 item scores. Lower observed values in SOWS-Gossop scores indicate a more positive clinical outcome.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 2 | 1 ± NA | -0.5 ± 3 |
| Day 3 | 1 ± NA | -2.2 ± 3.56 |
| Day 4 | — | -0.7 ± 5.03 |
| Day 5 | 1 ± NA | -0.3 ± 5.51 |
| Day 6 | — | 0.3 ± 5.03 |
| Day 7 | 1 ± NA | -2.5 ± 3.54 |
| Day 8 | 1.5 ± NA | -1.4 ± 4.72 |
| Day 9 | — | 2 ± 6 |
| Day 10 | 4 ± NA | -4.5 ± 0.71 |
| Day 11 | — | -0.3 ± 6.35 |
| Day 12 | 2 ± NA | -4.5 ± 0.71 |
| Day 13 | 4 ± NA | -1 ± 6.08 |
| Day 14 | 5 ± NA | -1 ± 6.08 |
| Day 15 | 2.7 ± NA | -4.3 ± 0.96 |
| Day 16 | — | 1.5 ± 6.45 |
| Day 17 | — | -4 ± 1.41 |
| Day 18 | — | -4 ± 1.41 |
| Day 19 | — | -4 ± 1.41 |
| Day 20 | — | -4 ± 1.41 |
| Day 21 | — | -4 ± 1.41 |
| Day 22 | — | -3.8 ± 2.49 |
| Day 23 | — | -2.7 ± 2.52 |
| Day 24 | -1 ± NA | -3 ± 3 |
| Day 25 | -1 ± NA | -4.5 ± 2.12 |
| Day 26 | — | -3 ± 3 |
| Day 27 | 1 ± NA | -4 ± 1.41 |
| Day 28 | — | -3.8 ± 2.87 |
The SOWS-H scale assesses subjective symptoms of opioid withdrawal. It is a subject-rated scale consisting of 19 items that are scored on a 5-point scale of 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, and 4 = extremely. The overall score is the simple sum of the 19 item scores. Lower observed values in SOWS-H scores indicate a more positive clinical outcome.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 2 | -4 ± NA | 0.3 ± 3.77 |
| Day 3 | -5 ± NA | -1 ± 4.3 |
| Day 4 | — | 2.3 ± 5.51 |
| Day 5 | -3 ± NA | 3 ± 6.24 |
| Day 6 | — | 3.3 ± 8.02 |
| Day 7 | -4 ± NA | 0 ± 5.66 |
| Day 8 | -2.5 ± NA | 1.8 ± 6.3 |
| Day 9 | — | 3.5 ± 7.59 |
| Day 10 | 0 ± NA | -1.5 ± 3.54 |
| Day 11 | — | 0.7 ± 6.35 |
| Day 12 | -3 ± NA | -4 ± 0 |
| Day 13 | 2 ± NA | -0.3 ± 8.14 |
| Day 14 | 1 ± NA | 0.7 ± 8.96 |
| Day 15 | 0.7 ± NA | -3.5 ± 1.29 |
| Day 16 | — | 4.3 ± 9 |
| Day 17 | — | -4 ± 1.41 |
| Day 18 | — | -3 ± 0 |
| Day 19 | — | -3 ± 0 |
| Day 20 | — | -3.5 ± 0.71 |
| Day 21 | — | -4 ± 0 |
| Day 22 | — | -2.8 ± 1.3 |
| Day 23 | — | -3.3 ± 2.08 |
| Day 24 | -5 ± NA | -2.3 ± 2.89 |
| Day 25 | -5 ± NA | -4.5 ± 0.71 |
| Day 26 | — | -3.3 ± 2.52 |
| Day 27 | -6 ± NA | -4 ± 0 |
| Day 28 | -3 ± NA | -3.8 ± 1.89 |
MCGI-R includes 2 items: A 7-point scale that allows clinicians to rate the severity of a subject's opiate withdrawal symptoms. A 4-point scale that allows clinicians to rate the degree of a subject's side effects from study drug. SEVERITY OF ILLNESS: 1. = No at all ill 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Among the most extremely ill subjects SIDE EFFECTS INDEX: 1. = None, study drug is producing no side effects 2. = Do not significantly interfere with subject's functioning 3. = Significantly interferes with subject's functioning 4. = Outweighs therapeutic effect
| score on a scale | Lofexidine Severity of Illness Scale Averages: | Placebo Severity of Illness Scale Averages: | Lofexidine Side Effects Index Averages: | Placebo Side Effects Index Averages: |
|---|---|---|---|---|
| Visit 2 | 1 ± NA | 1 ± NA | 1 ± NA | 1 ± NA |
| Visit 3 | 1 ± NA | 1.33 ± 0.471 | 1 ± NA | 1.33 ± 0.471 |
| Visit 4 | 1 ± NA | 1 ± NA | 1 ± NA | 1 ± NA |
| Visit 5 | 1 ± NA | 1 ± NA | 1 ± NA | 1 ± NA |
| EOS | 1 ± NA | 1 ± NA | 1 ± NA | 1 ± NA |
Includes: A 7-point scale for subjects to rate the severity of opiate withdrawal symptoms. A 4-point scale for subjects to rate the degree of side effects from their study drug. SEVERITY OF OPIATE WITHDRAWAL: 1. = No opiate withdrawal symptoms 2. = On the border between no to mild opiate withdrawal symptoms 3. = Mild opiate withdrawal symptoms 4. = Moderate opiate withdrawal symptoms 5. = Marked opiate withdrawal symptoms 6. = Severe opiate withdrawal symptoms 7. = The most severe opiate withdrawal symptoms that I have ever had SIDE EFFECTS INDEX (Scale B): 1. = None. The study drug has no side effects 2. = The study drug has slight side effects, but it does NOT significantly interfere with my day to day activities 3. = The study drug has moderate side effects, and it DOES significantly interfere with my day to day activities 4. = The study drug has severe side effects, and these side effects are greater than the relief from opiate withdrawal symptoms that it provides
| score on a scale | Lofexidine Severity of Opiate Withdrawal Averages: | Placebo Severity of Opiate Withdrawal Averages: | Lofexidine Side Effects Index Averages: | Placebo Side Effects Index Averages: |
|---|---|---|---|---|
| Day 2 | 1 | 1.33 ± 0.471 | 1 | 1 ± NA |
| Day 3 | 1 | 1 ± NA | 1 | 1 ± NA |
| Day 4 | — | 2 ± NA | — | 2 ± NA |
| Day 5 | 1 | 1.66 ± 0.471 | 1 | 1.66 ± 0.471 |
| Day 6 | — | 2 ± NA | — | 1.66 ± 0.471 |
| Day 7 | 1 | 1.66 ± 0.471 | 1 | 1.66 ± 0.471 |
| Day 8 | 1 | 2 ± NA | 1 | 2 ± NA |
| Day 9 | — | 1.66 ± 0.471 | — | 1.66 ± 0.471 |
| Day 10 | 1 | 2 ± NA | 1 | 1.66 ± 0.471 |
| Day 11 | — | 1.66 ± 0.471 | — | 1.66 ± 0.471 |
| Day 12 | 1 | 2 ± NA | 1 | 2 ± NA |
| Day 13 | 1 | 1.66 ± 0.471 | 1 | 1.66 ± 0.471 |
| Day 14 | 1 | 2 ± NA | 1 | 1.66 ± 0.471 |
| Day 15 | 1 | 1.66 ± 0.471 | 1 | 1.66 ± 0.471 |
| Day 16 | — | 2 ± NA | — | 1.66 ± 0.471 |
| Day 17 | — | 1.5 ± 0.5 | — | 1.5 ± 0.5 |
| Day 18 | — | 1.5 ± 0.5 | — | 2 ± NA |
| Day 19 | — | 1.5 ± 0.5 | — | 2 ± NA |
| Day 20 | — | 1.5 ± 0.5 | — | 2 ± NA |
| Day 21 | — | 1.5 ± 0.5 | — | 2 ± NA |
| Day 22 | — | 1.33 ± 0.471 | — | 1.66 ± 0.471 |
| Day 23 | — | 1 ± NA | — | 1 ± NA |
| Day 24 | 1 | 1.33 ± 0.471 | 1 | 1 ± NA |
| Day 25 | 1 | 1.5 ± 0.5 | 1 | 1 ± NA |
| Day 26 | — | 1.33 ± 0.471 | — | 1 ± NA |
| Day 27 | 1 | 1.5 ± 0.5 | 1 | 1 ± NA |
| Day 28 | — | 1.33 ± 0.471 | 1 | 1 ± NA |
Study day of participant discontinuation.
| Days to study discontinuation | Lofexidine | Placebo: Patient 1 | Placebo: Patient 2 | Placebo: Patient 3 |
|---|---|---|---|---|
| Time to Study Drug Discontinuation | 21 | 20 | 22 | 24 |
| Number concomitant medication | Lofexidine | Placebo: Patient 1 | Placebo: Patient 2 | Placebo: Patient 3 |
|---|---|---|---|---|
| Day 1-15: | 0 | 1 | 1 | 1 |
| Day 16- Day 28: | 1 | 1 | 1 | — |
The EQ-5D-5L is an instrument that evaluates preference for health status through 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of which are rated on 5 levels of severity. Each dimension ranges from a minimum of "0 - I have no problems or I am not" to a maximum of "5 - I am unable to or I am extremely". The dimensions are averaged together for a single score and the change in average score from baseline is recorded.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Scale | -0.40 ± NA | -0.13 ± 0.462 |
The SF-36 consists of 36 questions that measure various aspects of physical and mental well-being. Precoded values are recorded for each question ranging from 0-100, with a high score defined as a more favorable health status. The items are then averaged together to create the 8 scale scores which are averaged together to create a scale. The final value reported is the average change in the averaged scale scores from baseline to end of study.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Change in Short Form Health Survey (SF-36) Scale | -5 ± NA | -1.7 ± 2.52 |
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. The dimensions evaluated are: severity of sleep onset, sleep maintenance and early morning awakening problems, sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and distress caused by the sleep difficulties. A 5-point Likert scale is used to rate each item on a scale 0 to 4 for each of the 7 items, yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 15 | -1 ± NA | -4 ± 3 |
| EOS | -9 ± NA | 1 ± 1.73 |
The HADS is a self-reported screening tool for anxiety and depression in nonpsychiatric clinical populations. Responses are based on the relative frequency of symptoms over the preceding week. The scale consists of 14 items, with a subscale of 7 questions for anxiety and 7 questions for depression. Patients rate each item in the subscales on a 4-point scale ranging from 0 (absence) to 3 (extreme presence). Possible scores range from 0 to 21 for each subscale. An analysis of scores on the 2 subscales supported the differentiation of each mood state into 4 ranges: non-cases (scores 0 to 7), mild cases (scores 8 to 10), moderate cases (scores 11 to 15), and severe cases (scores 16 or higher), with lower values being favorable. The subscales are then combined for a total score ranging from 0 to 42. Higher scores indicate greater levels of anxiety or depression. The value reported is the average change from baseline to End of Study.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Change in Hospital Anxiety and Depression Scale (HADS) | -2 ± NA | -2.3 ± 3.51 |
A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 1 | 0 ± NA | -0.3 ± 0.82 |
| Day 2 | 0 ± NA | -1.5 ± 1 |
| Day 3 | 0 ± NA | -1.4 ± 1.82 |
| Day 4 | — | -0.7 ± 1.53 |
| Day 5 | -2 ± NA | -1.3 ± 1.15 |
| Day 6 | — | -1 ± 1 |
| Day 7 | -3 ± NA | -0.7 ± 1.53 |
| Day 8 | 0 ± NA | -0.8 ± 2.63 |
| Day 9 | — | -1 ± 0.82 |
| Day 10 | -1 ± NA | -0.5 ± 2.12 |
| Day 11 | — | -0.3 ± 1.15 |
| Day 12 | 0 ± NA | -1 ± 2.83 |
| Day 13 | -1 ± NA | -1 ± 2 |
| Day 14 | -1 ± NA | -1.3 ± 1.53 |
| Day 15 | -0.5 ± NA | -0.8 ± 1.5 |
| Day 16 | — | -1 ± 0 |
| Day 17 | — | -1 ± 1.41 |
| Day 18 | — | 0 ± 1.41 |
| Day 19 | — | -0.5 ± 2.12 |
| Day 20 | — | 0 ± 1.41 |
| Day 21 | — | -1.5 ± 2.12 |
| Day 22 | — | -1.2 ± 1.83 |
| Day 23 | — | 0 ± 1.41 |
| Day 24 | 0 ± NA | -0.7 ± 1.53 |
| Day 25 | 0 ± NA | -0.5 ± 2.12 |
| Day 26 | — | -1 ± 2 |
| Day 27 | 0 ± NA | 0 ± 2.83 |
| Day 28 | — | -0.5 ± 1.73 |
| Day 29 | 0 ± NA | 0.7 ± 1.53 |
| Day 30 | — | -0.7 ± 1.53 |
| Day 31 | 0 ± NA | -0.7 ± 1.53 |
| Day 32 | 0 ± NA | -1.5 ± 0.71 |
| Day 33 | — | -2 ± NA |
| Day 34 | — | -0.5 ± 0.71 |
| Day 35 | — | -1 ± 1 |
| Day 36 | — | -1 ± 1.41 |
| Day 37 | 0 ± NA | -0.8 ± 0.5 |
| Day 38 | — | -1 ± 1.41 |
| Day 39 | — | -1 ± 1.41 |
| Day 40 | 1 ± NA | -1.3 ± 2.08 |
| Day 41 | — | -1 ± NA |
| Day 42 | — | -1 ± 1.41 |
| Day 43 | -1 ± NA | -1 ± 1.41 |
| Day 44 | — | 0 ± 1.41 |
| Day 45 | -1 ± NA | -0.5 ± 0.71 |
| Day 46 | — | -0.5 ± 0.71 |
| Day 47 | 0 ± NA | 0 ± 1.41 |
| Day 48 | -1 ± NA | 0 ± 1.41 |
| Day 49 | — | -0.5 ± 0.71 |
| Day 50 | — | -0.5 ± 0.71 |
| Day 51 | -1 ± NA | 0 ± 1.41 |
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
| units on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 1 | 0 ± NA | 0 ± 0 |
| Day 2 | -2 ± NA | -1.3 ± 1.89 |
| Day 3 | 0 ± NA | -1.4 ± 2.51 |
| Day 4 | — | -0.3 ± 3.21 |
| Day 5 | -1 ± NA | -1 ± 2.65 |
| Day 6 | — | -0.3 ± 3.21 |
| Day 7 | -2 ± NA | -0.7 ± 2.89 |
| Day 8 | -0.5 ± NA | -1.8 ± 3.2 |
| Day 9 | — | -0.5 ± 3 |
| Day 10 | -2 ± NA | -2 ± 2.83 |
| Day 11 | — | -1 ± 2.65 |
| Day 12 | -2 ± NA | -2 ± 2.83 |
| Day 13 | -13 ± NA | -1.3 ± 3.21 |
| Day 14 | -1 ± NA | -1 ± 2.65 |
| Day 15 | -1 ± NA | -2 ± 2.31 |
| Day 16 | — | -0.5 ± 2.38 |
| Day 17 | — | -2 ± 2.83 |
| Day 18 | — | -2 ± 2.83 |
| Day 19 | — | -2 ± 2.83 |
| Day 20 | — | -2 ± 2.83 |
| Day 21 | — | -2 ± 2.83 |
| Day 22 | — | -2 ± 2.28 |
| Day 23 | — | 0 ± 1.41 |
| Day 24 | -2 ± NA | -1.7 ± 3.06 |
| Day 25 | -2 ± NA | -2.5 ± 2.12 |
| Day 26 | — | -1.7 ± 3.06 |
| Day 27 | -2 ± NA | -1.5 ± 0.71 |
| Day 28 | 1 ± NA | -1.5 ± 1.91 |
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 1 | 0 ± NA | 0 ± 0.63 |
| Day 2 | -1 ± NA | -0.8 ± 0.96 |
| Day 3 | -1 ± NA | 0.2 ± 1.3 |
| Day 4 | — | 0 ± 1 |
| Day 5 | -3 ± NA | 0 ± 1 |
| Day 6 | — | 0.7 ± 0.58 |
| Day 7 | -3 ± NA | 0.3 ± 0.58 |
| Day 8 | -0.5 ± NA | 0.3 ± 0.96 |
| Day 9 | — | 0 ± 0 |
| Day 10 | -1 ± NA | 0.5 ± 0.71 |
| Day 11 | — | 1 ± 1 |
| Day 12 | 0 ± NA | -0.5 ± 2.12 |
| Day 13 | -1 ± NA | 0.3 ± 0.58 |
| Day 14 | -1 ± NA | 0 ± 0 |
| Day 15 | -0.5 ± NA | 0 ± 0 |
| Day 16 | — | 0 ± 0 |
| Day 17 | — | 0 ± 0 |
| Day 18 | — | 1.5 ± 0.71 |
| Day 19 | — | 1.5 ± 0.71 |
| Day 20 | — | 0.5 ± 0.71 |
| Day 21 | — | -1 ± 1.41 |
| Day 22 | — | 0 ± 0.89 |
| Day 23 | — | 0.5 ± 0.71 |
| Day 24 | 0 ± NA | 0.3 ± 0.58 |
| Day 25 | 0 ± NA | 0.5 ± 0.71 |
| Day 26 | — | 0 ± 1 |
| Day 27 | -1 ± NA | 1.5 ± 0.71 |
| Day 28 | — | 0.5 ± 0.58 |
| Day 29 | 0 ± NA | 1.3 ± 0.58 |
| Day 30 | 0 ± NA | 0.3 ± 0.58 |
| Day 31 | 0 ± NA | 0.3 ± 0.58 |
| Day 32 | 0 ± NA | 0.5 ± 0.71 |
| Day 33 | — | 1 ± NA |
| Day 34 | — | 1 ± 1.41 |
| Day 35 | — | 0 ± 0 |
| Day 36 | — | 0 ± 0 |
| Day 37 | — | 0.5 ± 1 |
| Day 38 | — | 0 ± 0 |
| Day 39 | — | 0.5 ± 0.71 |
| Day 40 | 1 ± NA | 0.7 ± 1.15 |
| Day 41 | — | -1 ± NA |
| Day 42 | — | 0 ± 0 |
| Day 43 | -1 ± NA | 0 ± 0 |
| Day 44 | — | 1.5 ± 0.71 |
| Day 45 | -2 ± NA | 1 ± 1.41 |
| Day 46 | — | 1 ± 1.41 |
| Day 47 | -1 ± NA | 2 ± 1.41 |
| Day 48 | -1 ± NA | 1 ± 0 |
| Day 49 | — | 0.5 ± 0.71 |
| Day 50 | — | 0.5 ± 0.71 |
| Day 51 | -1 ± NA | 1 ± 0 |
The NRS of pain intensity is a unidimensional, segmented numeric version of the visual analog scale. A subject selects a whole number (0 to 10) that best indicates the intensity of his/her pain. The format consists of a horizontal line which is anchored by terms defining pain levels where 0 represents no pain and 10 represents worst pain imaginable.
| score on a scale | Lofexidine | Placebo |
|---|---|---|
| Day 1 | 0 ± NA | 0 ± 0 |
| Day 2 | -3 ± NA | -2.3 ± 1.53 |
| Day 3 | -2.5 ± NA | -1.6 ± 1.82 |
| Day 4 | — | -0.7 ± 2.89 |
| Day 5 | -3 ± NA | -1 ± 1.73 |
| Day 6 | — | 0.3 ± 1.15 |
| Day 7 | -2 ± NA | -1 ± 2.65 |
| Day 8 | 0.5 ± NA | -1.8 ± 2.06 |
| Day 9 | — | -0.8 ± 2.36 |
| Day 10 | -4 ± NA | -3 ± 1.41 |
| Day 11 | — | -1.7 ± 2.52 |
| Day 12 | -3 ± NA | -3 ± 1.41 |
| Day 13 | -2 ± NA | -2 ± 3 |
| Day 14 | -1 ± NA | -1 ± 1.73 |
| Day 15 | -1.3 ± NA | -2.8 ± 0.96 |
| Day 16 | — | -0.8 ± 2.06 |
| Day 17 | — | -3 ± 1.41 |
| Day 18 | — | -2.5 ± 0.71 |
| Day 19 | — | -2.5 ± 0.71 |
| Day 20 | — | -3 ± 1.41 |
| Day 21 | — | -3 ± 1.41 |
| Day 22 | — | -2.7 ± 1.97 |
| Day 23 | — | -1 ± 2.83 |
| Day 24 | -3 ± NA | -2 ± 2.65 |
| Day 25 | -3 ± NA | -2.5 ± 0.71 |
| Day 26 | — | -2 ± 2.65 |
| Day 27 | -4 ± NA | -0.5 ± 3.54 |
| Day 28 | — | -0.5 ± 1.73 |
| MME (morphine milligram equivalent) | Lofexidine | Placebo |
|---|---|---|
| Day 1 | -45 ± NA | -100 ± NA |
| Day 2 | -45 ± NA | -30 ± NA |
| Day 3 | -45 ± NA | -65 ± 49.5 |
| Day 4 | -45 ± NA | -63.3 ± 35.12 |
| Day 5 | -45 ± NA | -66.7 ± 40.41 |
| Day 6 | — | -80 ± 62.45 |
| Day 7 | -67.5 ± NA | -75 ± 25.98 |
| Day 8 | -67.5 ± NA | -60.8 ± 34.13 |
| Day 9 | — | -93.3 ± 50.08 |
| Day 10 | -67.5 ± NA | -45 ± 0 |
| Day 11 | -67.5 ± NA | -78.3 ± 29.3 |
| Day 12 | -67.5 ± NA | -67.5 ± 31.82 |
| Day 13 | — | -78.3 ± 29.3 |
| Day 14 | — | -145 ± NA |
| Day 16 | — | -155 ± NA |
| Day 20 | -67.5 ± NA | — |
| Day 22 | — | -15 ± NA |
| Day 23 | — | -20 ± NA |
| Day 24 | -67.5 ± NA | -20 ± NA |
| Day 25 | -67.5 ± NA | — |
| Day 27 | -67.5 ± NA | — |
| Day 28 | — | -20 ± NA |
| MME (morphine milligram equivalent) | Lofexidine | Placebo |
|---|---|---|
| Day 1 | -50 ± NA | -50 ± NA |
| Day 2 | -50 ± NA | -50 ± NA |
| Day 3 | -50 ± NA | -50 ± 0 |
| Day 4 | -50 ± NA | -50 ± 0 |
| Day 5 | -50 ± NA | -51.7 ± 2.89 |
| Day 6 | — | -58.3 ± 14.43 |
| Day 7 | -75 ± NA | -65 ± 17.32 |
| Day 8 | -75 ± NA | -52.1 ± 21.95 |
| Day 9 | — | -74.2 ± 1.44 |
| Day 10 | -75 ± NA | -56.3 ± 26.52 |
| Day 11 | -75 ± NA | -66.7 ± 14.43 |
| Day 12 | -75 ± NA | -75 ± 0 |
| Day 13 | — | -66.7 ± 14.43 |
| Day 14 | — | -72.5 ± NA |
| Day 16 | — | -77.5 ± NA |
| Day 20 | -75 ± NA | — |
| Day 22 | — | -7.5 ± NA |
| Day 23 | — | -10 ± NA |
| Day 24 | -75 ± NA | -10 ± NA |
| Day 25 | -75 ± NA | — |
| Day 27 | -50 ± NA | — |
| Day 28 | — | -10 ± NA |
Collected over Day 1 of drug administration through 30 day follow up, up to 57 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lofexidine | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Lofexidine | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/3 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/1 | 1/3 |
| RashSkin and subcutaneous tissue disorders | 0/1 | 1/3 |
| YawningRespiratory, thoracic and mediastinal disorders | 0/1 | 1/3 |
| LethargyNervous system disorders | 0/1 | 1/3 |
| Age, Categorical(Participants) | Lofexidine | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 4 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Lofexidine | Placebo | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 1 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Lofexidine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 0 | 3 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lofexidine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 3 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Nov 2019, 3 months.
Results were first posted in Oct 2024, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lofexidine
USWM, LLC (dba US WorldMeds)